IN2014CH00378A - - Google Patents

Download PDF

Info

Publication number
IN2014CH00378A
IN2014CH00378A IN378CH2014A IN2014CH00378A IN 2014CH00378 A IN2014CH00378 A IN 2014CH00378A IN 378CH2014 A IN378CH2014 A IN 378CH2014A IN 2014CH00378 A IN2014CH00378 A IN 2014CH00378A
Authority
IN
India
Prior art keywords
factor
plasma
levels
impurity
chromatography
Prior art date
Application number
Other languages
English (en)
Inventor
Neelima Vadde
Samaddar Mitali
Nuvula Ashok
Chakraborty Zinia
Swapna Sagar Duggineni
Devi Komath Uma
Original Assignee
Hemarus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US14/530,840 priority Critical patent/US9663553B2/en
Application filed by Hemarus Therapeutics Ltd filed Critical Hemarus Therapeutics Ltd
Priority to PCT/IN2015/000055 priority patent/WO2015114664A1/en
Priority to EP15717662.9A priority patent/EP3099702A1/en
Priority to IN378CH2014 priority patent/IN2014CH00378A/en
Publication of IN2014CH00378A publication Critical patent/IN2014CH00378A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size selective separation, e.g. size exclusion chromatography, gel filtration, permeation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/10—Process efficiency

Landscapes

  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN378CH2014 2014-01-29 2015-01-28 IN2014CH00378A (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US14/530,840 US9663553B2 (en) 2014-01-29 2014-11-03 Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma
PCT/IN2015/000055 WO2015114664A1 (en) 2014-01-29 2015-01-28 An integrated process for the production of therapeutics (human albumin, intravenous immunoglobulins, clotting factor viii and clotting factor ix) from human plasma
EP15717662.9A EP3099702A1 (en) 2014-01-29 2015-01-28 An integrated process for the production of therapeutics (human albumin, intravenous immunoglobulins, clotting factor viii and clotting factor ix) from human plasma
IN378CH2014 IN2014CH00378A (es) 2014-01-29 2015-01-28

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN378CH2014 IN2014CH00378A (es) 2014-01-29 2015-01-28

Publications (1)

Publication Number Publication Date
IN2014CH00378A true IN2014CH00378A (es) 2015-08-07

Family

ID=52991912

Family Applications (1)

Application Number Title Priority Date Filing Date
IN378CH2014 IN2014CH00378A (es) 2014-01-29 2015-01-28

Country Status (4)

Country Link
US (1) US9663553B2 (es)
EP (1) EP3099702A1 (es)
IN (1) IN2014CH00378A (es)
WO (1) WO2015114664A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111991571A (zh) * 2020-08-12 2020-11-27 湖州师范学院 一种柱上低pH病毒灭活的方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9932388B2 (en) * 2014-11-13 2018-04-03 Hemarus Therapeutics Limited Chromatographic process for producing high purity fibrinogen and thrombin
US9556253B2 (en) * 2014-12-02 2017-01-31 Hemarus Therapeutics Limited Process for increased yield of immunoglobulin from human plasma
US11814442B2 (en) 2017-06-12 2023-11-14 Kamada Ltd. Immunoglobulin compositions and process for obtaining the same
CN108733099B (zh) * 2018-05-31 2020-08-11 上海药明生物技术有限公司 低pH孵育和中和的自动调节系统及方法
CN111499736B (zh) * 2020-04-28 2021-04-30 国药集团武汉血液制品有限公司 一种静注covid-19人免疫球蛋白的制备方法
CN112574296B (zh) * 2020-12-30 2023-05-19 中国医学科学院输血研究所 一种模拟IVIg的多人份混合人血浆IgG样品的分离纯化方法
CN113831405B (zh) * 2021-11-17 2024-04-30 华兰生物工程重庆有限公司 一种人血白蛋白的纯化方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) 1942-02-09 1945-12-04 Research Corp Protein product and process
JPS5128727A (es) 1974-09-04 1976-03-11 Canon Kk
JPS52125609A (en) 1976-04-09 1977-10-21 Green Cross Corp:The Purification of agglutination factor viii
US4228154A (en) 1979-02-26 1980-10-14 Armour Pharmaceutical Company Purification of plasma albumin by ion exchange chromatography
US4371520A (en) 1981-10-28 1983-02-01 The Green Cross Corporation Process for preparing immunoglobulin suitable for intravenous injection
US4639513A (en) 1984-02-02 1987-01-27 Cuno Inc. Intravenously injectable immunoglobulin G (IGG) and method for producing same
US5614500A (en) 1983-03-04 1997-03-25 The Scripps Research Institute Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography
FR2543448A1 (fr) 1983-04-01 1984-10-05 Rhone Poulenc Spec Chim Procede de fractionnement du plasma
US6258938B1 (en) 1983-10-28 2001-07-10 Ne Medical Center Hospital, Inc. Method for the purification and isolation of blood clotting proteins using conformation specific antibodies
JPS63108000A (ja) 1986-05-15 1988-05-12 Green Cross Corp:The 第８因子の精製方法
DE3640513A1 (de) 1986-11-27 1988-06-09 Biotest Pharma Gmbh Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates
DE3877529T2 (de) 1987-10-23 1996-11-07 Centre Regional De Transfusion Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat und dessen therapeutische Verwendung.
DE3914869C1 (es) 1989-05-05 1990-08-09 Biotest Pharma Gmbh, 6072 Dreieich, De
US5138034A (en) 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
FR2651437A1 (fr) 1989-09-05 1991-03-08 Lille Transfusion Sanguine Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total.
DK162233C (da) * 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
FR2672604B1 (fr) 1991-02-07 1995-05-05 Pasteur Merieux Serums Vacc Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue.
DK0573605T3 (da) 1991-03-01 2001-01-02 Rhone Poulenc Rorer Int Fremstilling af faktor IX
IT1262899B (it) 1992-03-27 1996-07-22 Sclavo Spa Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano
FR2690444B1 (fr) 1992-04-22 1995-07-13 Rucheton Marcel Procede de preparation d'une solution d'albumine plasmatique purifiee.
US5286849A (en) 1992-07-14 1994-02-15 Alpha Therapeutic Corporation Purification of factor IX
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
US5714583A (en) * 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
DK2272870T3 (da) 1998-06-09 2013-08-05 Csl Behring Ag Fremgangsmåde til fremstilling af immunoglobuliner med henblik på intravenøs indgivelse og andre immunoglobulin-lignende produkter.
DE19932782A1 (de) 1999-07-14 2001-01-18 Biotest Pharma Gmbh Verfahren zur chromatographischen Fraktionierung von Plasma oder Serum, so erhaltene Präparate und deren Verwendung
US6893639B2 (en) 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
US20040106779A1 (en) 2002-12-03 2004-06-03 Bigler Douglas E. Modified factor IX preparation
CN102924565A (zh) * 2004-06-07 2013-02-13 厄普弗朗特色谱公司 血浆或者血清蛋白的分离
MX2007002085A (es) 2004-08-20 2007-07-19 Prometic Biosciences Ltd Esquemas de aislamiento y purificacion consecutivos de proteinas mediante cromatografia de afinidad.
US20070049732A1 (en) 2005-09-01 2007-03-01 Zurlo Eugene J Ultra-high yield intravenous immune globulin preparation
WO2007063129A2 (en) 2005-12-02 2007-06-07 Novozymes A/S Insolation of peptides , polypeptides and proteins
WO2007136327A1 (en) 2006-05-22 2007-11-29 Ge Healthcare Bio-Sciences Ab A method of producing igg
ES2294976B1 (es) 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111991571A (zh) * 2020-08-12 2020-11-27 湖州师范学院 一种柱上低pH病毒灭活的方法

Also Published As

Publication number Publication date
WO2015114664A1 (en) 2015-08-06
EP3099702A1 (en) 2016-12-07
US20150210737A1 (en) 2015-07-30
US9663553B2 (en) 2017-05-30

Similar Documents

Publication Publication Date Title
IN2014CH00378A (es)
ES2813398T3 (es) Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
JP2022116038A (ja) 二重特異性抗体を製造する方法、二重特異性抗体及びこのような抗体の治療的使用
RU2018106364A (ru) Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств
HRP20161740T1 (hr) Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b
AR097651A1 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
SI3042917T1 (en) PROTITELES AGAINST N3PGL AMILOID BETA PEPTID AND THEIR APPLICATION
CA2926301A1 (en) Low acidic species compositions and methods for producing and using the same
EP3308798A3 (en) Polypeptides and antibodies for treating hbv infection and related diseases
AU2015228649A1 (en) Method for preparing human plasma proteins
MX2016001601A (es) Separacion de anticuerpos biespecificos y subproductos de produccion de anticuerpos biespecificos utilizando cromatografia de hidroxiapatita.
EA201491564A1 (ru) Осаждение фракции i-iv-1 иммуноглобулинов из плазмы
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
TWI610937B (zh) 用於降低血漿來源免疫球蛋白組成物之血栓性栓塞可能性的方法
ZA202203681B (en) Compositions and methods for the treatment of viral infections
WO2015021423A3 (en) Purification of chimeric fviii molecules
Prasad et al. Intravenous immunoglobulin in pediatrics: A review
EA201990593A1 (ru) Непрерывный способ для снижения гетерогенности терапевтического белка
EA201691834A1 (ru) Новый способ очистки гонадотропина
HRP20220197T1 (hr) Antitijela protiv il-22r
JP2017507132A (ja) 抗体プロセス
UA85741C2 (ru) Способ получения иммуноглобулина
Weng et al. Anti-human platelet antigen-1a immunoglobulin G preparation intended to prevent fetal and neonatal alloimmune thrombocytopenia
RU2018114657A (ru) Антагонисты IL-17C для лечения и/или предупреждения атопического дерматита
US11149079B2 (en) Process for the preparation of immunoglobulin G (IgG)